Beijing Tiantan Biological Products (600161) H2 2024 earnings summary

Executive summary

• Sales revenue increased 16.47% year-over-year, driven by higher product sales volume and price increases.

• Net profit attributable to shareholders rose 39.42% compared to the same period last year.

Financial highlights

• Operating income reached ¥6,033.53 million, up 16.47% year-over-year.

• Operating profit was ¥2,562.81 million, a 41.98% increase year-over-year.

• Net profit attributable to shareholders was ¥1,547.43 million, up 39.42% year-over-year.

• Basic EPS was ¥0.78, up 39.42% year-over-year.

• Total assets at year-end were ¥15,847.94 million, up 11.70% from the start of the year.

Outlook and guidance

• Continued focus on increasing plasma collection and expanding product sales is expected.